RTI, Tutogen announce new name for proposed merged company

19 January 2008

Regeneration Technologies, Inc. (RTI) and Tutogen Medical, Inc. today announced that with the proposed merger of the two companies, they will ask RTI shareholders to approve a new company name - RTI Biologics, Inc. The stock will continue to trade on the Nasdaq Global Market under RTI's trading symbol, RTIX.

On 13 November 2007 the two had companies announced  signing a definitive agreement to combine the two companies in a tax-free stock-for-stock exchange. Under the terms of the merger agreement, Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own.

Upon completion of the merger, RTI and Tutogen stockholders would own approximately 55 per cent and 45 per cent respectively of the combined company on a diluted basis.

The newly combined and newly named company RTI Biologics will be positioned as a leader in biologics, a growing area in the healthcare industry and a key strength for both companies.

"Our new company name is centred around 'Biologics,' which can include a wide array of biological solutions. These are areas that represent strong growth and great promise in healthcare," said Brian K. Hutchison, RTI's chairman, president and CEO. "We feel it is important to begin this new endeavour with a fresh brand that better represents the strengths of both RTI and Tutogen"

While the company name will become RTI Biologics, the combined company will continue to use and leverage the strengths of both the BioCleanse and Tutoplast brand names, which are well-known throughout the medical community as the standards for sterilisation, safety and quality of orthopaedic and membrane tissues, respectively.